Pro Medicus expands U.S. footprint and leans into AI to strengthen competitive edge

Pro Medicus Limited ( (AU:PME) ) has issued an announcement.

Pro Medicus has secured three significant U.S. contracts, including a A$90 million, seven-year cloud-based deal with Beth Israel Lahey Health in Boston, plus agreements with University of Maryland Medical System and Tidal Health. These wins expand its presence in key regions, validate demand for its cardiology and broader imaging offerings, and support its claim to one of the largest addressable markets in medical imaging software.

Chief executive Dr Sam Hupert said recent contract renewals and new deals undermine fears that AI will broadly disrupt all software providers, arguing instead that AI will enhance Pro Medicus’ competitive moat and productivity. The company is leveraging AI to boost output from a small, highly skilled development team without restructuring or job cuts, positioning itself to benefit from AI-driven efficiency gains and increased demand for advanced imaging workflows.

The most recent analyst rating on (AU:PME) stock is a Buy with a A$147.00 price target. To see the full list of analyst forecasts on Pro Medicus Limited stock, see the AU:PME Stock Forecast page.

More about Pro Medicus Limited

Pro Medicus Limited is an Australian health technology company specialising in diagnostic imaging software and cloud-based radiology platforms for large hospital systems and health networks. Its proprietary full-stack solution supports AI-enabled workflows at scale and has established a significant footprint in the U.S. market, including major academic and regional healthcare providers.

YTD Price Performance: -39.95%

Average Trading Volume: 362,060

Technical Sentiment Signal: Hold

Current Market Cap: A$13.82B

See more insights into PME stock on TipRanks’ Stock Analysis page.